Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.26. Hemispherx BioPharma shares last traded at $0.25, with a volume of 149,044 shares changing hands.
Hemispherx BioPharma Stock Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- What Are Some of the Best Large-Cap Stocks to Buy?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is the S&P/TSX Index?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is a Stock Market Index and How Do You Use Them?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
